The core idea behind interventional oncology is deceptively simple: if you can see a tumor clearly under imaging, you can often treat it without opening the body. High-resolution computed tomography, ultrasound, and magnetic resonance imaging allow physicians to navigate instruments to lesions deep within organs, destroying or starving them with millimeter-level precision. What began decades ago with image-guided biopsies, using needles to sample suspicious tissue, has evolved into a therapeutic arsenal of remarkable sophistication. The field’s trajectory, the authors note, illustrates the accelerating pace of innovation in oncology, transforming procedures that once seemed impossible into routine clinical practice.

Among the most consequential of these techniques is trans-arterial embolization, which has reshaped the treatment of liver cancer in particular. Rather than flooding the entire body with chemotherapy, interventionalists thread a catheter through the arterial system until its tip reaches the vessel feeding the tumor. Therapeutic agents are then delivered directly into that blood supply, often combined with particles that block the vessel altogether, cutting off the tumor’s nourishment. The approach delivers a concentrated payload to the malignancy while sparing functional liver tissue, a critical consideration in an organ whose reserve capacity often determines whether a patient can tolerate further treatment.

Equally transformative are percutaneous ablation techniques, in which needles or probes are placed directly into tumors and used to destroy them in situ. Thermal ablation, the most widely used family of methods, kills cancer cells by applying extreme heat through radiofrequency energy or microwaves, or by freezing tissue with cryoablation. These procedures have opened new pathways for patients who might otherwise have been poor candidates for invasive surgery, whether because of tumor location, coexisting illness, or insufficient organ reserve. Crucially, the authors emphasize, such advances have not merely provided alternatives to conventional treatment; they have created entirely new therapeutic possibilities, both for previously untreatable conditions and for combination strategies that make curative approaches achievable for more patients.

Perhaps the most scientifically exciting frontier lies at the intersection of interventional oncology and immunotherapy, the class of drugs that unleashes the body’s own immune defenses against cancer. Recent discoveries have revealed that many interventional procedures do more than physically destroy tumor tissue; they can actively stimulate a systemic immune response. When thermal ablation breaks down tumor cells, it releases tumor antigens, molecular fingerprints that the immune system can recognize and remember. In some patients this triggers a phenomenon known as the abscopal effect, in which the local treatment of one lesion appears to provoke immune-mediated regression of untreated tumors elsewhere in the body. The effect offers tantalizing avenues for combination therapies that pair targeted physical intervention with immunological activation, and research into this synergy is one of the field’s most active areas.

The growing power of interventional oncology is inseparable from its integration into the multidisciplinary machinery of modern cancer care. Interventional oncologists now sit regularly on tumor boards, the committees where medical oncologists, surgical oncologists, radiation oncologists, and other specialists jointly design each patient’s therapeutic strategy. This collaboration has produced more nuanced and personalized treatment sequences. Interventional procedures can be used to downstage tumors, shrinking them so that curative surgery becomes feasible, or to treat residual disease and oligoprogression, the isolated growth of a few lesions after conventional therapy has otherwise controlled the cancer. The ability to interleave treatments in this way has measurably improved outcomes and expanded options for patients who once faced limited choices.

Looking forward, the technological horizon appears remarkably bright. Artificial intelligence and machine learning are enhancing the precision of image-guided procedures, helping clinicians plan trajectories and interpret imaging with increasing accuracy. Robotic systems are extending the reach and steadiness of interventional techniques beyond what human hands alone can achieve, while advanced imaging technologies now provide real-time views of tumor biology and treatment response. Nanotechnology and molecular medicine are opening new frontiers in targeted therapy delivery, promising treatments that are more precise, more effective, and more personalized than ever before. The convergence of these computational, robotic, and biological tools suggests that the next decade of interventional oncology may be even more transformative than its last.

The field’s progress, however, is not without obstacles. Pereira and Helmberger are candid about the challenges ahead: the discipline must continue to strengthen its evidence base through rigorous clinical trials, and quality assurance frameworks need to be standardized across institutions. One concrete response is the International Accreditation System for Interventional Oncology Services, known as IASIOS, which aims to certify that centers performing these procedures meet consistent standards of training, equipment, and patient care. Training programs must also evolve, and the visibility of interventional oncology among medical students and fellows must grow to meet the rising demand for skilled interventionalists. The COVID-19 pandemic, though deeply disruptive, accelerated certain aspects of the field’s development, as supportive and palliative interventions and telemedicine-guided procedures gained prominence when conventional care pathways were strained.

Scholarly publishing has a role to play in sustaining this momentum, and the launch of CVIR Oncology itself reflects the field’s maturation. The journal is designed as a bridge between oncological specialties, welcoming contributions from interventional radiologists, medical and surgical oncologists, radiation oncologists, and basic scientists alike. The editorial logic is that cross-disciplinary dialogue breaks down silos: a surgical oncologist’s insights on post-procedural outcomes can refine interventional techniques, just as an immunologist’s findings can enhance procedural efficacy. By publishing both basic science and clinical research, the journal aims to translate laboratory discoveries into practical therapies, supporting the shift toward personalized medicine. As an open-access publication, it also ensures that practitioners in resource-limited settings can access the same evidence base as those in major academic centers.

Ultimately, the promise of interventional oncology extends beyond its technical achievements to something more human: the quality of patients’ lives. By offering less invasive treatments with fewer complications and shorter recovery times, the field is making cancer therapy more tolerable, benefiting patients and society alike. From primary liver and kidney tumors to metastatic disease, and from palliative symptom control to curative intent, interventional oncology is redefining what is possible across the entire spectrum of malignancy. The story, as its pioneers tell it, is one of continuous innovation and adaptation, and as the field stands on the threshold of new discoveries, its practitioners are confident that it will play an increasingly vital role in a future where cancer treatment is not only more effective, but also more humane.

Subject of Research: The evolution of interventional oncology as a minimally invasive, image-guided fourth pillar of multidisciplinary cancer treatment

Article Title: The evolution of interventional oncology: pioneering a new era in cancer care

Article References: The evolution of interventional oncology: pioneering a new era in cancer care. (n.d.). https://doi.org/10.1007/s44343-025-00002-6

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00002-6

Keywords: interventional oncology, interventional radiology, thermal ablation, trans-arterial embolization, immunotherapy, abscopal effect, liver cancer, artificial intelligence, multidisciplinary cancer care, IASIOS accreditation, minimally invasive treatment, CVIR Oncology

The first domain the authors address is artificial intelligence, and they deliberately reject the framing that has dominated the conversation. The question, they insist, is not whether AI will replace the interventional oncologist, but which interventional oncologists will master AI and use it to redefine the standard of care. The applications are no longer speculative. AI-assisted needle tracking, intraprocedural image registration and automated target confirmation are moving from research prototypes into clinical tools. Automated tumour contouring and ablation margin prediction are reducing the cognitive burden of treatment planning while improving reproducibility across operators and institutions. Perhaps most transformative is radiomics-based early response assessment, which promises to detect treatment failure before conventional imaging shows any change, a paradigm shift for follow-up and retreatment decisions that builds on the foundational radiomics work published in Nature Communications by Aerts and colleagues. Beyond the procedure itself, AI is beginning to attack the administrative and workflow inefficiencies that erode clinical capacity, from scheduling optimisation to structured reporting. The cumulative effect, the authors argue, is a reduction in cognitive load that frees the physician to focus on what remains irreplaceable: clinical judgement, the patient relationship and procedural expertise. Their conclusion is blunt and likely to circulate widely: those who master these tools will not be replaced by AI; they will replace those who did not.

The second domain is the physical environment in which image-guided cancer therapy is delivered. Interventional radiology was born from the insight that imaging and therapy are not sequential but simultaneous, a principle traceable to Dotter and Judkins’ description of transluminal angioplasty in 1964 and to Seldinger’s landmark catheter technique a decade earlier. Gangi’s own group helped define the hybrid era in the early 1990s, when they first described combining computed tomography with C-arm fluoroscopy, uniting cross-sectional precision with real-time dynamic guidance in a single interventional environment. That innovation proved its worth rapidly in one of the most clinically urgent corners of the field: cancer pain management. CT-guided procedures ranging from coeliac plexus neurolysis to vertebroplasty established early that the specialty could address not only tumour burden but the suffering it causes, an integration of palliation within an oncological framework that tumour boards, the authors note, have been slow to fully recognise. Three decades of progressive integration have since brought ultrasound, interventional MRI, PET-CT fusion planning and real-time computational overlay into environments no other specialty has claimed as its own. The vision for 2030 is the fully integrated CT, angiography and MR suite as a standard of care in academic centres, with interventional MRI transitioning from a specialised capability to a broadly implemented clinical platform. Gangi’s institution has treated endometriosis, renal tumours, uterine adenomyosis and bone metastases under real-time MR guidance for nearly two decades. What was exceptional in 2007, the authors contend, must become routine by 2030.

The third domain is evidence, and here the lecture delivers its harshest self-assessment. Interventional oncology has earned its seat at the tumour board, but that seat was built case by case through outcomes data that could no longer be ignored. Thermal ablation, transarterial chemoembolisation, radioembolisation and vertebroplasty have each demonstrated clinical value, supported by standardisation efforts such as the terminology and reporting criteria established by Goldberg and colleagues in Radiology and the clinical validation recommendations for liver tumour ablation advanced by Lencioni, de Baère and colleagues. Yet presence at the table is not influence at the table, and the authors draw a sharp distinction between the two. The currency at a multidisciplinary meeting is data, and the persistent absence of phase III randomised controlled trials in interventional oncology is identified as the specialty’s most significant vulnerability. Tumour boards respect what they can systematically evaluate, and excellent results must be matched by an equally excellent evidence architecture. The challenge for the coming decade is to move from the retrospective series that formed the foundation of the field toward prospective, randomised and ideally multicentre trials.

Importantly, the authors do not treat randomised trials as the only legitimate form of evidence. They argue that prospective registries, pragmatic multicentre studies and robust real-world data analyses should be regarded as integral components of a mature evidence ecosystem, capturing patient heterogeneity, treatment sequencing, institutional variation and the rapid evolution of devices in ways conventional trials cannot always accommodate. These approaches are not a lower level of ambition but a complement that generates clinically meaningful data for multidisciplinary decision-making and guides the design of future randomised studies. Several frontier areas demand particular attention. The synergy between thermal ablation and immunotherapy, including the abscopal effect as a therapeutic target, is generating prospective data that could transform interventional oncology’s role in systemic cancer treatment, with trials such as the combination of tremelimumab and ablation in advanced hepatocellular carcinoma pointing the way. Radiomics-based biomarkers are moving toward regulatory approval. Theranostics and radiopharmaceutical combinations represent an emerging paradigm. And the outpatient ablation centre model, delivering image-guided therapy ambulatorily at lower cost and with reduced institutional dependency, may prove to be the most disruptive development of the decade.

The fourth domain is the most personal: the relationship between the interventional oncologist and the patient. The authors pose a question they have asked audiences across Europe, and the answer is always the same. Ask a patient who performed their surgery and they name the surgeon. Ask who performed their biopsy or their ablation and they name the building. This asymmetry, they argue, is not inevitable but a consequence of how the specialty has historically organised itself around a technician model in which the patient is referred, the procedure is performed and the patient is returned. That model is both clinically suboptimal and institutionally fragile, because it makes the practitioner replaceable. The physician model is their prescription for the future: dedicated outpatient consultations, a full therapeutic relationship with continuity of care and structured follow-up, inpatient management when required, and accreditation through the International Accreditation System for Interventional Oncology Services as institutional validation of the standard. When a patient has a named interventional oncologist, someone they can call, someone who reviews their imaging and explains a recurrence, the specialty becomes indispensable. The authors are explicit that this is not a turf battle in the pejorative sense but a claim to clinical ownership that outcomes justify, and they note that their doors remain open to surgeons who recognise the value of minimally invasive, image-guided therapy. The transformation from proceduralist to physician, they write, is not a threat to the specialty’s identity but its completion.

The fifth domain is mentorship, and it is here that the tribute to Thierry de Baère becomes most direct. The challenges of 2030 will be met by those being shaped today, and de Baère understood this better than most. He did not simply transmit techniques; he transmitted a philosophy of rigour, intellectual honesty and care that extended beyond the procedure, building careers with the same intentionality he brought to clinical innovation. The authors describe him as an architect of people. The mentor’s role, they argue, is not to produce competent operators but to produce the next generation of leaders, physicians who can navigate a multidisciplinary tumour board, design a prospective trial and inspire a trainee as they themselves were once inspired. Resilience, ethics and clinical empathy cannot be learned from a textbook; they are modelled in the culture of a department, in how a senior colleague responds to a complication, and in whether a trainee is protected or exposed when things go wrong. Professional bodies including CIRSE and IASIOS are working toward harmonised, competency-based training curricula, building on standards of practice such as those published by Crocetti, de Baère and colleagues on thermal ablation of liver tumours, and the EBIR and EBIR-IO certification pathways are meaningful steps. But certification, the authors caution, is a floor, not a ceiling. What the specialty owes the next generation is not compliance with a minimum standard but the ambition to exceed it.

The trajectory the lecture traces is remarkable when viewed as a whole. From Seldinger’s needle and Dotter’s catheter, through the CT-fluoroscopy hybrids of the 1990s and the MR-guided suites of the 2000s, interventional oncology has built a specialty that is less invasive, less expensive, less disabling and less time-consuming than the alternatives it has progressively replaced. The authors frame the field’s past, present and future as a continuous arc of technical courage, clinical ambition and intellectual generosity, one that aligns closely with the legacy of Thierry de Baère, whose work and mentorship helped establish precisely these foundations. The vision they articulate is of a multidisciplinary, evidence-driven, scientifically rigorous and clinically integrated discipline, recognised as the fourth pillar of oncological treatment alongside surgery, medical oncology and radiation therapy.

The work ahead, as the authors summarise it, is a five-point charge to the specialty: master AI before it masters the agenda; own the multimodal suite before others claim it by default; lead the multidisciplinary team with data rather than deference; claim the patient as a physician rather than a technician; and build the future by investing unconditionally in those who will carry it forward. It is a message aimed squarely at trainees and early-career physicians, but its implications reach hospital administrators, tumour boards and device developers alike. The authors close with a reminder that carries the urgency of a countdown: 2030 is closer than we think, and it begins today.

Subject of Research: The future of interventional oncology, including artificial intelligence, hybrid imaging suites, evidence development, clinical ownership and mentorship, as outlined in the inaugural Thierry de Baère Lecture.

Article Title: Interventional oncology 2030: challenges and opportunities for the next generation — in honour of Thierry de Baère

Article References: Gangi, A., & Palussière, J. (2026). Interventional oncology 2030: challenges and opportunities for the next generation — in honour of Thierry de Baère. CVIR Oncology, 2(1), Article 18. https://doi.org/10.1007/s44343-026-00048-0

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00048-0

Keywords: interventional oncology, artificial intelligence, thermal ablation, hybrid imaging suites, radiomics, immunotherapy, abscopal effect, multidisciplinary tumour boards, IASIOS accreditation, mentorship, Thierry de Baère, randomised controlled trials